阿托伐他汀钠治疗慢性肾功能不全脂蛋白紊乱的临床研究

The clinical research on Lipoprotein disorder of chronic renal failure with Lipitor treatment

目的观察阿托伐他汀钠治疗慢性肾功能不全脂蛋白紊乱的临床效果。方法选择慢性肾功能不全患者60例,简单随机分成治疗组30例及对照组30例,两组均在α-酮酸结合低蛋白低磷饮食治疗及西医对症处理的基础上;对照组结合非诺贝特治疗,治疗组结合阿托伐他汀钠治疗。观察胱抑素CHO、ApoA1、ApoB100、HDL-C、LDL-C、Scr、ALB治疗前后的变化,Cys-C采用乳胶颗粒增强比浊法测定,CHO、ApoA1、ApoB100、HDL-C、LDL-C、Scr、ALB采用常规方法测定。结果治疗组治疗前后各项指标相比均有显著差异P<0.01或P<0.05,治疗组治疗后CHO、ApoA1、ApoB100、HDL-C、LDL-C、(Cys-C)、Scr、ALB水平与对照组相比有显著性差异,P<0.01或P<0.05;结论阿托伐他汀钠能延缓患者肾功能进展恶化,调整血脂紊乱。

OBJECTIVE To observe the levels of Serum Scr,CHO,ApoA1,ApoB100,ALB,HDL-C and LDL-C effected by Lipitor of chronic renal failure and evaluating clinical effect of Lipitor.METHODS 60 patients with chronic renal failure were randomly divided into treatment group and control group.basic treatment was adopted α-Ketoacid and low protein low phosphorum diet and correcting crun,control group apart from adopted basic treatment drug and integrated Lipilfen,treatment group apart from adopted basic treatment drug and integrated Lipitor,to observe respective changes Scr,CHO,ApoA1,ApoB100,ALB,HDL-C and LDL-C in pretreatment and posttreatment,Scr,CHO,ApoA1,ApoB100,ALB,HDL-C and LDL-C were determined simultaneously using routine methods.RESULTS The levels of plasma Scr,CHO,ApoA1,ApoB100,ALB,HDL-C and LDL-C of the cases with CRF at pretreatment were markedly higher than those at posttreatment（P0.01 or P0.05）.After completion of therapy,There was significantly different between treatment group and control group（P0.05 or P0.01）.CONCLUSION Lipitor has significantly better effects on treatment of CRF,to postpone progress of renal function,to adjust lipoprotein disorder.